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In 2010, the WHO celebrated the 30th anniversary of the smallpox eradication. Ironically, infections caused by viruses related to
smallpox are being increasingly reported worldwide, including Monkeypox, Cowpox, and Vaccinia virus (VACV). Little is known
about the human immunological responses elicited during acute infections caused by orthopoxviruses. We have followed VACV
zoonotic outbreaks taking place in Brazil and analyzed cellular immune responses in patients acutely infected by VACV. Results
indicated that these patients show a biased immune modulation when compared to noninfected controls. Amounts of B cells are
low and less activated in infected patients. Although present, T CD4+ cells are also less activated when compared to noninfected
individuals, and so are monocytes/macrophages. Similar results were obtained when Balb/C mice were experimentally infected
with a VACV sample isolated during the zoonotic outbreaks. Taking together, the data suggest that zoonotic VACVs modulate
speciﬁc immune cell compartments during an acute infection in humans.
1.Introduction
Thirty years after smallpox eradication the interest in Or-
thopoxvirus infections has been renewed by the potential
use of Smallpox as a biological weapon [1] and the sub-
stantial increase in reports of zoonotic poxvirus infections
throughout the world [2, 3], including the emergence of
Monkeypox virus (MPV) in Africa and the USA [4], the
emergence of Vaccinia virus ( V A C V )i n f e c t i o n si nB r a z i l[ 5–
10], the maintenance of VACV in milking buﬀaloes in India
[11, 12], and the increasing numbers of Cowpox virus (CPV)
infections in Europe and Central Asia [13].
At the time of smallpox eradication, human immune
responses to the Variola virus infection were not well un-
derstood, nor the response against live VACV strains used
for vaccination. In the last years, however, our knowledge
on how humans respond immunologically to Orthopoxvirus
infections was greatly improved [14–20]. Most eﬀorts have
been directed to understand the mechanisms of protection
against subsequent infections conferred by previous vaccina-
tion. In this respect, it is now clear that antibodies have a
major role in long-term protection against Orthopoxviruses,
with relatively high titers that remain stable for decades,
whereas CD8+ and CD4+ T cell responses decline slowly2 Clinical and Developmental Immunology
over time [14, 21–23]. On the other hand, the immune
mechanisms involved in replication control and clearing
of an Orthopoxvirus primary infection are still not fully
understood, but essential roles for the innate and adaptive
immunity have been demonstrated [24]. In the innate
immunity context, studies have shown that the complement
systemandNKcellsareimportant tocontroltheseinfections
until the adaptive responses arise; the loss of these functions
results frequently in host death [25–27]. For the adaptive
responses, the importance and eﬃciency of CD8+ Tc e l l s
to control and clear poxviruses in the absence of antibody
production depend greatly on the animal model and the
virus species used [20]. Studies using VACV inoculation in
mice have shown that CD4+ T and B cells are able and
suﬃcient to eliminate the virus. However, this is apparently
not the case when animals are infected with species-speciﬁc
orthopoxviruses such as Ectromelia virus [28–30]. In the
latter case, CD8+ T cells are vital to contain the virus early in
infection, as mice lacking CD8+ T cells succumb early due to
high viral load. However, CTL function alone is insuﬃcient
to clear the virus. At later stages, antibodies become essential
for virus elimination and survival. Evidences come from
studies showing the inability of animals deﬁcient in B or
CD4+ T cells to eﬀectively control and clear the infection
[29–31]. Moreover, passive transfer of B cells or immune
serum restores virus elimination capabilities in infected
animals [30]. The requirement for CD4+ T cells is clear as
robust-speciﬁc antibody responses fail to develop in animals
lacking these cells [28]. Similarly, CD4+ Tc e l lf u n c t i o ni s
essential for an optimal CTL response [20]. The most likely
scenario is that both cell and humoral immunities work
complementarily to contain Orthopoxvirus acute infections.
The active circulation of orthopoxviruses in Brazil has
been reported since the early 1960s. From 1999 onwards,
manyoutbreaksofanexanthematicdiseaseaﬀectinghumans
and cattle alike were associated with such viruses. As isolates
became available, the agent of such outbreaks was demon-
stratedtobetheVACV.Infectionsareusuallyzoonotic,asthe
virus spreads from sick lactating cows to their handlers, lead-
ing to the formation of vesicle and ulcers on the hands, arms,
torso and face of sick individuals (reviewed in [32, 33]).
Here we analyzed aspects of the cellular immune
responses in patients acutely and naturally infected by VACV
during zoonotic outbreaks taking place in Brazil. Our results
indicate that these infections trigger a virus-speciﬁc immune
modulation biased mainly towards macrophage and T CD4+
and B cell functions.
2.MaterialsandMethods
2.1. Study Population. The study population consisted of
53 individuals showing signs of poxvirus infection, ages
between 18 and 70 years, both genders, all living in the
outbreak areas. Patients were classiﬁed as acutely infected
on the basis of the occurrence of typical clinical symptoms
(mainly the presence of nonhealed pustules and vesicles),
VACV DNA detection in serum samples or lesion ﬂuids,
and virus isolation from lesion swabs. Eighteen healthy
individuals, with no signs of infection, 29 to 55 years old,
alsoresidingattheoutbreakareas,wereenlistedandincluded
in the study as a noninfected control group. All patients
were properly examined by a physician and those presenting
apparent clinical signs of any other disease, infectious or not,
were not included in the study.
2.2. Virus Isolation from Animals and Humans. Fluid from
suppurated lesions was collected using a sterile swab and
maintained in MEM culture media for transportation.
Viruses were isolated by inoculation in chorio-allantoic
membranes of embryonated chicken eggs (CAMs) and am-
pliﬁed in VERO cells. Viruses were puriﬁed and character-
ized by neutralization tests using anti-VACV antibodies and
by nucleotide sequencing of Orthopoxvirus-speciﬁc genes
after PCR ampliﬁcation using VACV-speciﬁc primers [34].
2.3. Phylogenetic Analysis. The hemagglutinin (HA) gene
nucleotide sequences from the isolated viruses and from
other Orthopoxviruses (retrieved from GenBank) were
aligned on the basis of codon positions using the CLUSTAL
W software. Alignments were manually edited and used
to perform phylogenetic analyses using the Neighbor-
joining and Maximum-likelihood methods implemented
in Mega3 and Paup∗4.0b10. GenBank accession numbers
are as follows: Vaccinia virus: Western Reserve (VACV-
WR) (AY243312), VACV-Lister (AY678276), Modiﬁed
virus Ankara (VACV-MVA) (AY603355), Copenhagen
(VACV-COP) (M35027), VACV-Wyeth (Z99051), VACV-
TTan (U25662), VACV-Malbran (AY146624), Br-Hu-1
(FJ173000), Br-Hu-2 (EF063677), Br-An-1 (FJ173001), Br-
An-2 (FJ173002), Br-An-3 (FJ173003), Passatempo (VACV-
PSTV) (DQ070848), Cantagalo (VACV-CTGV) (AF229247),
Arac ¸atuba (VACV-ARAV) (AY523994), Guarani P2 (VACV-
GP2V) (DQ206437), Muria´ e (VACV-MURV) (DQ247770),
VACV-BeAn58058 (DQ206442), Belo Horizonte (VACV-
VBH) (DQ206435), VACV-IOC (AF229248), Guarani P1
(VACV-GP1V) (DQ206436), VACV-SPAn232 (DQ222922),
Lister Butantan (VACV-LTBUT) (EF175985); Buﬀalopox
virus (BFPV-3906) (AF375077); Cowpox virus Brighton Red
(CPXV-BR) (AF482758)’Rabbitpox virus rev (RBPV-rev)
(AY484669); Ectromelia virus Moscow (ECTV) (AF012825);
Camelpox virus: CMS (CMLV-CMS) (AY009089), M-96
(CMLV-M96) (AF438165); Variola virus: Garcia-1966
(VARV-GAR) (U18338) and Bangladesh-1975 (VARV-BSH)
(L22579).
2.4. Cell Preparation and Proliferation Assay. Peripheral
blood mononuclear cells (PBMCs) were isolated by Ficoll-
diatriazoate density gradient centrifugation (LSM, Organon
Teknica, Charleston, SC), cultured in triplicate (106
cells/well) in 96-well ﬂat-bottom plates, and stimulated
with either UV-inactivated VACV-WR for 6 days or PHA
(at 2.5μg/mL to test cell viability) for 3 days. Tritiated
thymidine (1μCi/well) was added to the cultures for 6 hours
before completion of the incubation period. Incorporation
of [3H]thymidine was determined by liquid scintillation
counting. Data wereanalyzedand presentedas countings per
minute (CPM) (calculated as the mean experimental cpm ±
SD − mean control cpm ± SD).Clinical and Developmental Immunology 3
2.5. Detection of Cytokine Levels by Cytometric Bead Array
Immunoassay (CBA). Microbeads consisted of six distinct
populations, unique on their Type 3 ﬂuorescence intensity
(FL-3), each coupled to mAb against one of the six Th1/Th2
and regulatorycytokines (IL-2, IL-4, IL-5, IL-10, TNF-α,a n d
IFN-γ). Captured cytokines were detected using six diﬀerent
mAbs coupled to PE (FL-2). A total of 1,800 events/gate
were acquired. Standard curves were plotted using a four-
parameter logistic curve ﬁtting model. Cytokine concentra-
tions weredetermined using standard curves. If a samplehad
a cytokine concentration below the detection limit for the
assay, a value of 0 was attributed for statistical purposes.
2.6. Cell Phenotype Analysis. Cells were quantiﬁed after
in vitro antigenic stimulation with UV-inactivated VACV
using mouse anti-human monoclonal antibodies (MoAbs)
conjugatedwithFITCorPE,speciﬁcforcell-surfacemarkers.
Cultured cells were washed in PBS containing 1% BSA
plus 0.1% sodium azide (FACS buﬀer) and stained with
monoclonalantibodiesagainstCD3,CD4,andCD8forTcell
populations, CD19 for B cells, CD16 and CD56 for NK cells,
and CD14 for monocytes. Same cells were labeled simul-
taneously with antibodies against costimulatory molecules
(HLA-DR, CD25, CD69, CD28, CD80, and CD86). Cell
preparations were ﬁxed in FACS ﬁx solution and stored at
4◦C in the dark. A total of 30,000 events/tube were acquired
using a FACScalibur ﬂow cytometer (Becton Dickinson) set
up to measure forward (FSC), side (SSC) light scatters, FITC
(FL-1), and PE (FL-2) ﬂuorescence. CELLQuest software was
used for data acquisition and analysis.
2.7. Statistical Analysis. Analyses were performed using
GraphPad Prism version 3.0 software. The following non-
parametric tests were performed: (1) Mann-Whitney test to
compare two groups (noninfected × infected individuals);
and (2) Wilcoxon test to compare cultures stimulated and
nonstimulated. The statistical analysis was performed by
using the median values of each group.
2.8. Animal Experiments. Groups of 10 four-week-old male
Balb/C mice were used. Animals were intranasally infected
with 104 PFUs of a zoonotic VACV sample in PBS. Ten
days after infection, animals were anesthetized and blood
was collected. PBMCs were obtained as mentioned and
cell surface markers (CD4, CD14, CD25, and CD69) were
detected as described above.
2.9. Ethics Statement. The human study protocol complied
with the Brazilian National Council of Health regulations
and was approved by the Instituto Ren´ e Rachou Review
Board (IRR IRB) under protocol number 03/2006. All
patientssignedinformedconsents.Animalexperimentswere
conducted in accordance with the Brazilian Federal Law
number 11.794 (October 8th, 2008), which regulates the
scientiﬁcuseofanimals,andIACUCguidelines.Allprotocols
were approved by the Committee of Ethics for Animal
Experimentation (CETEA) at UFMG under permit 9/2009,
valid through April 2014. The CETEA-UFMG is aﬃliated
to the National Council of Animal Experimentation Control
(CONCEA).
3. Results
3.1. Characterization of the Population Involved in the Study.
Since 1999, yearly outbreaks of an exanthematic disease
aﬀecting humans and cattle have been reported among poor
pockets of population in the rural countryside of Southeast
Brazil. In most cases, the isolated infectious agent causing
the zoonotic outbreaks was the VACV. We have followed
outbreaks taking place in farms at the Minas Gerais State,
SE, Brazil, from 2005 to 2009. The studied group consisted
of 53 aﬀected human patients, who were clinically evaluated,
and 18 noninfected and healthy individuals living at the
sameareasaﬀectedbytheoutbreaks(controlgroup).Clinical
symptoms of the infection included high fever, headache,
muscle pain, nausea, lymphangitis, and the appearance of
pleiomorphic lesions on hands, forelimbs and eventually in
the face, torso, and genitals. In all patients, acute lesions were
associated with a roseolar erythema and localized edema
leading to the formation of vesicles [8]. As pointed out in
previousstudies[5–8],thediseaseisoccupational,aspersons
dealing with infected dairy cattle were those presenting signs
of infection. Importantly, out of 53 infected patients, at least
10werevaccinatedagainstsmallpoxinthepast,asconﬁrmed
by visualization of a typical vaccination scar in their left arm.
3.2. Virus Samples Isolated during the Studied Outbreaks Are
Genetically Consistent with Previously Described Circulating
VACV Isolates. Twovirusisolateswereobtainedfromhuman
patients during the studied outbreaks and characterized,
together with three other samples isolated from cattle at the
sameareas(hereinreferredasVACV-Br-Hu-1,VACV-Br-Hu-
2,VACV-Br-An-1,VACV-Br-An-2,andVACV-Br-An-3).The
hemagglutinin (HA) genes from all viruses were sequenced,
and they presented a signature of 18-nucleotide deletion
also observed in previously isolated Brazilian VACVs [5–
7, 32, 34]. Phylogenetic analyses based on the HA nucleotide
sequences demonstrated that all isolated viruses cluster
together with other Brazilian VACV samples isolated in
the past, and none cluster with attenuated vaccine strains
includingVACV-Lister,theLister-derivedButant˜ astrain(L T -
B U T ) ,M V A ,o rW y e t h( D r y v a x )( Figure 1). The data con-
ﬁrmed that the viruses involved with the studied outbreaks
are consistent with those involved in past described VACV
zoonotic outbreaks in Brazil.
3.3. PBMCs from Infected Individuals Proliferated and Pro-
duced IFNγ after Stimulation with VACV Antigens. In order
to evaluate the immune responsiveness of the infected
individuals to VACV antigens, we stimulated their peripheral
blood mononuclear cells (PBMCs) ex vivo.C e l l sw e r e
expose to either PHA (Figure 2(a))o rU V - t r e a t e dV A C V
(Figure 2(b)), and cell proliferation was determined by [3H]
thymidineincorporation.Uponmitogenicorantigenicstim-
ulation, PBMCs from VACV-infected individuals presented a
signiﬁcantly (P = 0.01) higher cellular proliferative response4 Clinical and Developmental Immunology
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Figure 1: Phylogenetic relationships between the VACV samples obtained in this study and other relevant poxviruses. The phylogenetic
tree was constructed by the Neighbor-joining method and used hemagglutinin gene nucleotide sequences from various orthopoxviruses,
including Brazilian Vaccinia virus (VACV) isolates and other poxviruses. The Tamura3-parameter nucleotide substitution model was used
and the reliability of the branching patterns was tested by 1000 bootstrap pseudo-replicates. Bootstrap values above 70% are shown. The
scale bar represents 1% nucleotide sequence divergence. Samples are as follows: Zoonotic Brazilian Vaccinia virus isolated from humans
(VACV-Br-Hu-1, VACV-Br-Hu-2) or cattle (VACV-Br-An-1, VACV-Br-An-2, VACV-Br-An-3)—labeled with stars (∗); other Vaccinia virus
strains isolated in Brazil—Passatempo (VACV-PSTV), Cantagalo (VACV-CTGV), Arac ¸atuba (VACV-ARAV), Guarani P2 (VACV-GP2V)
(DQ206437), Muria´ e (VACV-MURV), VACV-BeAn58058, Belo Horizonte (VACV-VBH), VACV-SPAn232, Guarani P1 (VACV-GP1V);
reference Vaccinia virus strains—Western Reserve (VACV-WR), VACV-Lister, Modiﬁed virus Ankara (VACV-MVA), Copenhagen (VACV-
COP), VACV-Wyeth, VACV-TTan, VACV-Malbran, Lister Butantan (VACV-LTBUT); VACV-IOC (AF229248), Buﬀalopox virus (BFPV-
3906) (AF375077); other Orthopoxviruses—Cowpox virus Brighton Red (CPXV-BR), Rabbitpox virus rev (RBPV-rev), Ectromelia virus
Moscow (ECTV), Camelpox virus CMS (CMLV-CMS), Camelpox virus M-96 (CMLV-M96), Variola virus Garcia-1966 (VARV-GAR), and
Variola virus Bangladesh-1975 (VARV-BSH).
when compared to PBMCs from noninfected subjects. Cells
from both groups showed lower proliferative responses
when mock-treated with culture medium, as expected (Fig-
ures 2(a) and 2(b)). Mathew and coworkers [35]d e m o n -
strated that PBMCs from individuals who received VACV
immunization presented transient decreased proliferative
responses toPHA,anti-CD3, andVACV antigens whencom-
paring the proliferative responses from single individuals
before and after vaccination. However, this was not observed
when we compared antigen-induced proliferation in PBMCs
from naturally infected patients to noninfected individuals.
Next, we evaluated the levels of cytokines secreted by
PBMCs on the culture supernatants of cells obtained from
all subjects. The amounts of secreted IFNγ produced after
VACV antigenic stimulation were signiﬁcantly higher in
infectedindividuals(P<0.001)(Figure 3).ThisresultdiﬀersClinical and Developmental Immunology 5
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Figure 2: Proliferative responses in PBMCs of individuals infected or not by zoonotic Vaccinia virus. Peripheral blood mononuclear cells
(PBMCs) from patients infected or not with zoonotic Vaccinia virus were cultured in the presence of PHA (a), UV-inactivated virus (b)
or mock-treated (medium). After 6 days of stimulus, the cell proliferation was determined by [3H]thymidine incorporation. Statistical
signiﬁcance (P values), based on the median values of each group, is presented on the graphs. CPM: counts per minute.
Table 1: Mean percentage of T (CD3+,C D 4 +,C D 8 +) and B (CD19+)l y m p h o c y t e s ,N Kc e l l s( C D 1 6 +) and monocytes (CD14+)o nP B M C s
from noninfected or zoonotic Vaccinia virus infected individuals after stimulation with virus antigens.
Cell phenotype
Groups CD3+ CD4+ CD8+ CD19+ CD16+ CD14+
Noninfected 72.5 ±3.95 2 .1 ± 5.21 9 .2 ±2.1 16.4 ± 3.3 22.8 ±6.52 .9 ±1.4
Infected 79.2 ±4.9∗ 58.3 ± 3.22 0 .3 ±2.01 1 .4 ±2.5∗∗ 19.8 ±7.44 .4 ±1.4
PBMCs: peripheral blood mononuclear cells.
∗P = 0.008, when infected and noninfected groups were compared.
∗∗P = 0.03, when infected and noninfected groups were compared.
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Figure 3: Interferon-gamma production in PBMCs of individuals
infected or not by zoonotic Vaccinia virus. Peripheral blood mono-
nuclear cells (PBMCs) from patients infected or not with zoonotic
Vaccinia virus were cultured in the presence of UV-inactivated virus
or mock-treated (medium). After 6 days of stimulus, the amount
of IFN-γ produced in the cultures’ supernatants was measured
by cytometric bead array immunoassay. Statistical signiﬁcance (P
values), based on the median values of each group, is presented.
fromapreviousobservationinwhichasingleVACV-infected
patient was studied and presented diminished amounts of
IFNγ in comparison to noninfected controls [8]. Mock-
treated cells did not produce signiﬁcant amounts of IFNγ
(Figure 3). Analysis of IL-2, IL-4, IL-5, IL-10, and TNF-α
from both groups did not show detectable amounts of these
cytokines in culture supernatants.
3.4. CD4+ TC e l l s ,b u tN o tC D 8 + TC e l l s ,A r eL e s sA c t i v a t e di n
Infected Patients When Compared to Noninfected Individuals.
Analysis of the mean percentage of T and B lymphocytes,
NK cells and monocytes were performed on PBMCs from
both groups after ex vivo stimulation with UV-treated
VACV. These analyses demonstrated an increase on the
mean percentage of T cells (CD3+)( P = 0.008) and
a surprisingly lower mean percentage of B lymphocytes
(CD19+)( P = 0.03) in infected individuals (Table 1).
Therefore, these results were associated with a signiﬁcant
increase in CD3+ :CD19+ ratio in infected individuals when
compared to the noninfected group (P = 0.01). No
signiﬁcant diﬀerences were observed in the mean percentage
of T lymphocyte subsets (CD4+ and CD8+) and in the
mean values of monocytes (CD14+) and NK cells (CD16+)6 Clinical and Developmental Immunology
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Figure 4:CD4+ T-cellactivationstatusinPBMCsfromindividualsinfectedornotbyzoonoticVacciniavirus.Peripheralbloodmononuclear
cells (PBMCs) from patients infected or not with zoonotic Vaccinia virus were cultured in the presence of UV-inactivated virus or mock-
treated (medium). After 72 hours of stimulus, cells were ﬁxed, counted, and the following parameters were evaluated by ﬂow cytometry
using speciﬁc mouse anti-human antibodies: (a) percentage of CD4+ T lymphocytes expressing HLA-DR surface activation marker; (b)
percentage of CD4+ T lymphocytes expressing CD25 surface activation marker; (c) percentage of CD4+ T lymphocytes expressing CD69
surface activation marker. Statistical signiﬁcance (P values), based on the median values of each group, is presented on the graphs.
(Table 1). Apart from the unexpected decrease in total B
cell amounts in infected patients, other results seemed to
be consistent with typical late immune responses during an
acute viral infection, especially considering T-cell responses.
However, when T-cell subsets coexpressing CD25, CD69,
CD28, CTLA-4, and HLA-DR, as activation markers, were
analyzed on PBMCs from infected and noninfected individ-
uals, a diﬀerent picture emerged. Expression of HLA-DR,
CD25, and CD69 on the surface of CD4+ Tl y m p h o c y t e sw a s
lower in infected patients (P = 0.04, P = 0.05, and P = 0.05,
resp.) (Figure 4). Importantly, we observed no diﬀerences in
the cell activation status when PBMCs were either stimulated
with VACV antigens or mock-treated. Expression levels of
CD28 and CTLA-4 on CD4+ T lymphocytes from the two
human groups were not signiﬁcantly diﬀerent (not shown).
On the other hand, CD8+ T lymphocytes from infected indi-
viduals presented a signiﬁcant increase in CD28 expression
(P = 0.03) (Figure 5(a)). No signiﬁcant diﬀerences were
observed when cells were stimulated with VACV antigens
or mock-treated. Analysis of HLA-DR, CD25, and CD69 on
CD8+ T lymphocytes did not show any statistical diﬀerences
between the groups (not shown).
3.5. CD14+ Cells and B Cells Are Less Activated in Infected
Patients When Compared to Noninfected Individuals. Relative
Amounts of Regulatory CD8 T Cells Are Also Smaller in
Infected Subjects. Some Orthopoxviruses, such as the CPV
and VACV, are known to interfere with the APC’s functions
by disrupting MHC classes I- and II-mediated antigen
presentation [36–39]. Therefore, although monocytes were
present in PBMCs from infected and noninfected patients
in comparable amounts, it seemed appropriate to check
whether these cells were activated. Thus, the expression
of the activation markers CD80 and CD86 on the surfaceClinical and Developmental Immunology 7
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Figure 5: CD28 molecule expression and evaluation of regulatory T CD8+ cells in PBMCs from individuals infected or not by zoonotic
Vaccinia virus. Peripheral blood mononuclear cells (PBMCs) from patients infected or not with zoonotic Vaccinia virus were cultured in the
presence of UV-inactivated virus or mock-treated (medium). After 72 hours of stimulus, cells were labeled with mouse anti-human CD8
antibodies and anti-human CD28 antibodies. The percentages of CD8+ CD28+ (a) and CD8+ CD28− (b) T-cell subsets were determined by
ﬂow citometry. Statistical signiﬁcance (P values), based on the median values of each group, is presented on the graphs.
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Figure 6: Monocyte (CD14+) activation status in PBMCs from individuals infected or not by zoonotic Vaccinia virus. Peripheral blood
mononuclear cells (PBMCs) from patients infected or not with zoonotic Vaccinia virus were cultured in the presence of UV-inactivated
virus or mock-treated (medium). After 72 hours of stimulus, cells were ﬁxed, counted, and the following parameters were evaluated by ﬂow
cytometry using speciﬁc mouse anti-human antibodies: (a) percentage of monocytes (CD14+) expressing CD80 surface activation marker;
(b) percentage of monocytes (CD14+) expressing CD86 surface activation marker. Statistical signiﬁcance (P values), based on the median
values of each group, is presented on the graphs.
of macrophages/monocytes (CD14+) after stimulation with
VACVantigenswereevaluated.Thepercentageofmonocytes
expressing such markers was signiﬁcantly lower in infected
patients (P = 0.01 and P = 0.002, resp.) (Figures 6(a) and
6(b)). Likewise, the expression of CD80 and CD86 on the
surface of B lymphocytes (CD19+) was measured. Not only
the total amounts of B lymphocytes were lower in infected
patients (Table 1), but these cells were also less activated
when compared to uninfected individuals, as judged by the
low percentage of CD19+ CD80+ and CD19+ CD86+ cells on
PBMCs from the ﬁrst group (P = 0.01) (Figures 7(a) and
7(b)). Finally, we also evaluated relative amounts of regula-
tory CD8+ TL y m p h o c y t e s( C D 8 +/CD28+ to CD8+/CD28−
ratio) in PBMCs from all subjects. PBMCs from infected
subjects presented signiﬁcant decrease (P = 0.01) in the
relative amounts of regulatory CD8 T Lymphocytes when8 Clinical and Developmental Immunology
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Figure 7: B cell (CD19+) activation status in PBMCs from individuals infected or not by zoonotic Vaccinia virus. Peripheral blood
mononuclear cells (PBMCs) from patients infected or not with zoonotic Vaccinia virus were cultured in the presence of UV-inactivated
virus or mock-treated (medium). After 72 hours of stimulus, cells were ﬁxed, counted, and the following parameters were evaluated by
ﬂow cytometry using speciﬁc mouse anti-human antibodies: (a) percentage of B lymphocytes (CD19+) expressing CD86 surface activation
marker; (b) percentage of B lymphocytes (CD19+) expressing CD80 surface activation marker. Statistical signiﬁcance (P values), based on
the median values of each group, is presented on the graphs.
compared to noninfected individuals (Figure 5(b)). This is
an interesting ﬁnding since increase in CD8+ regulatory
cells have been demonstrated to inhibit CD4 proliferation.
Overall, no signiﬁcant diﬀerences were seen between cells
stimulated with VACV antigens or mock-treated.
3.6. Mice Infected with a VACV Zoonotic Isolate Also Show
Modulation in Speciﬁc Compartments of Their Immune Re-
sponses. In order to further conﬁrm the zoonotic VACV’s
ability to modulate speciﬁc immune responses, we infected
mice with an isolated VACV sample and analyzed the cellular
immune response elicited during the onset of the acute
disease. Although not all parameters studied for humans
were evaluated in the mice experiments, the obtained results
were comparable to those observed in infected persons.
Total counts of macrophages/monocytes (CD14+ cells) were
lower in the infected group (P<0.001) (Figure 8(a)),
and the expression of CD25 surface activation marker was
diminished on CD4+ T cells when compared to noninfected
animals (P = 0.01) (Figure 8(b)). Relative amounts of
speciﬁc CD8+ T cells were higher in infected animals when
comparedtothenoninfectedgroup(P = 0.01)(Figure 8(c)).
4. Discussion
Orthopoxvirus-mediated modulation of immune responses
in humans is poorly demonstrated due to the inherent
diﬃculties to study populations infected by virulent virus
strains. In this respect, Hammarlund and colleagues [19]
have shown that MPV infecting human cells is able to
evade CD4+ and CD8+ T cell responses through an MHC-
independent mechanism, although, in this case, they did not
evaluate immune responses in acutely infected patients.
On a previous work we had shown that one studied
VACV-infected patient produced low amounts of IFNγ [8].
However, when a larger group of infected patients were
analyzed in the current study, this pattern was not observed.
Variations on the levels of IFNγ produced by diﬀerent
individuals is usually high, as exempliﬁed by the individual
dot distribution in Figure 3, and that may explain the fact
that this cytokine level was low on the study performed
before. Indeed, cytokine production may vary enormously
in ﬁeld patients as a result of diﬀerent ages; diﬀerent genetic
backgrounds; other existing microbial infections; immuno-
logicalandnutritionalstatus;generalhealthconditions.Such
variations in IFNγ p r o d u c t i o nh a sb e e ns e e ni nﬁ e l ds t u d i e s
of malaria, for instance, among other infectious diseases
[40, 41].
We have also shown that speciﬁc compartments of the
human immune response to zoonotic VACV acute infections
are virus-modulated. That could be inferred from a marked
virus-induced decrease in the activation status of CD4+ T
cells, B cells, and macrophage/monocytes. This apparent
bias in the virus immune evasion strategy may suggest
that these speciﬁc responses are those responsible for the
impairment of VACV replication success in the human
host. Indeed, viruses in general, and specially poxviruses
(due to their large coding capacity), encode a multitude of
proteins that interfere with diverse immunological functions
of the host [42–44]. Moreover, viruses are usually very
didactical in demonstrating which components of the host
immune system are determinants to their replicative success
by encoding evasion proteins that speciﬁcally aﬀect such
components. The fact that humans acutely infected by
virulent VACV showed an apparent virus-induced mod-
ulation of macrophages/monocytes, CD4+ Ta n dBc e l l sClinical and Developmental Immunology 9
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Figure 8: Aspects of the immune responses in mice infected or not with zoonotic Vaccinia virus. Peripheral blood mononuclear cells
(PBMCs) from mice either infected with a zoonotic Vaccinia virus isolate or noninfected were cultured for 72 hours in the presence of
UV-inactivated VACV. After incubation, cells were labeled with speciﬁc antibodies and analyzed by ﬂow cytometry. (a) Percentage of total
monocytes (CD14+); (b) percentage of CD4+ T lymphocytes expressing the CD25 surface activation marker; (c) percentage of CD8+ T
lymphocytes. Bars represent the mean results from 10 animals. Error bars and P values are indicated.
suggests that these may be essential and perhaps suﬃcient
for virus clearing and disease resolution during an acute,
primary infection. Indeed, VACV disruption of MHC class-
II-restricted antigen presentation has been described [37–
39]. On the other hand, we found that, CD8+ Tc e l l
responses are apparently not modulated by the infections,
suggesting that CD8+ T cell responses may have a lesser
impact on the resolution of VACV primary infections, as
hypothesized by some authors [20, 28–31]. One limitation
to the study is the size of the analyzed group, which
comprises 53 orthopoxvirus-infected human patients and
18 noninfected individuals living in the same aﬀected areas.
Notiﬁcation of human poxvirus infections is not mandatory
inBrazil,andidentiﬁcationofpatientsisdonethroughactive
random search. The fact has impaired our ability to enroll a
larger number of patients. At this point, we cannot provide
mechanistic explanations for the ﬁndings presented here.
To that end, mice infections with mutant viruses lacking
speciﬁc immune evasion genes could help to understand
how orthopoxviruses induce such speciﬁc and polarized
modulation of the host immune response.
The VACV outbreaks taking place in Brazil represent an
important opportunity to understand aspects of naturally
acquired Orthopoxvirus infections in a population scale.
Although of undeniable importance, most studies on human
immune responses to primary Orthopoxvirus infections have
been carried out in voluntary recipients of the smallpox
vaccine. Because Orthopoxvirus’i n f e c t i o n si nh u m a n sa r e
relatively rare nowadays, vaccinated persons represent the
most obvious alternative to study immune responses to
these viruses in a population scale. However some aspects
must be considered. First, vaccine strains are usually10 Clinical and Developmental Immunology
chosen because they are attenuated and avirulent, and only
cause adverse events on a small number of individuals
under very speciﬁc conditions [45, 46]. Thus, the responses
elicited against them may not be necessarily identical to the
immune responses generated during infection with a more
virulent Orthopoxvirus strain. Secondly, the attenuation
process frequently leads to the loss of genes that are not
essential for virus growth in vitro, such as those involved
in host’s immune evasion mechanisms. Therefore, VACV
vaccine strains generally lack many such genes. This is
the case of the Dryvax strain, which lacks genes coding
for the interferon (IFN)-α/β viroceptor, an ankyrin-like
protein (ortholog of VARV-BSHB18R) and tumor necrosis
factor (TNF)-α receptor homolog [47]; and the Modiﬁed
Vaccinia Ankara (MVA) strain, which lacks many immune-
evasion genes and is not replicative in most mammal
cells [48]. These viruses’ relative deﬁciency in modulating
host’s immunity may result in infections whose patterns
are deﬁnitely diﬀerent from those caused by more virulent
Orthopoxvirus strains. Finally, most studies are carried out
in controlled environments and conditions which include
predetermined human populations; inoculum size; sites of
inoculation; careful followup of vaccinees. These conditions,
although necessary, do not mimic natural infections, and
that may have an impact on how the individual’s immune
system responds to the infection.
5. Conclusions
Despite the fact that immunomodulatory genes are present
in the genome of VARV, the most notorious human poxvi-
ral pathogen [49], the impact of virus-encoded immune
evasion strategies during human infections by poxviruses
is largely unknown. We have studied 53 patients acutely
infected by zoonotic VACVs and analyzed their innate and
adaptative immune responses. Our results suggested that
speciﬁc cell subsets including B cells, CD4+ T cells, and
macrophage/monocytes are speciﬁcally modulated by the
infection,incomparisontouninfectedpatients.Ontheother
hand, CD8+ T cell responses seem to be unaltered, mirroring
typical CTL response patterns during a viral infection. These
results are compatible with a model in which CD4+ T
cell-dependent antibody responses are the main responsible
for disease control and virus clearance during primary
Orthopoxvirus’ infections [28, 30]. This study represents
the ﬁrst attempt to analyze aspects of the human immune
responses during the onset of acute, naturally acquired
infections by orthopoxviruses.
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